A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 25,770 shares of VIR stock, worth $190,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,770
Previous 28,200 8.62%
Holding current value
$190,698
Previous $250,000 22.8%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$7.26 - $10.7 $17,641 - $26,001
-2,430 Reduced 8.62%
25,770 $193,000
Q2 2024

Aug 12, 2024

BUY
$7.63 - $12.66 $32,206 - $53,437
4,221 Added 17.6%
28,200 $250,000
Q1 2024

May 09, 2024

SELL
$8.6 - $11.9 $9,451 - $13,078
-1,099 Reduced 4.38%
23,979 $242,000
Q4 2023

Feb 08, 2024

BUY
$7.76 - $10.29 $110,742 - $146,848
14,271 Added 132.05%
25,078 $252,000
Q2 2023

Aug 09, 2023

BUY
$23.2 - $27.29 $19,882 - $23,387
857 Added 8.61%
10,807 $265,000
Q1 2023

May 08, 2023

BUY
$22.26 - $30.85 $14,424 - $19,990
648 Added 6.97%
9,950 $231,000
Q4 2022

Feb 07, 2023

SELL
$19.96 - $28.22 $12,794 - $18,089
-641 Reduced 6.45%
9,302 $235,000
Q2 2022

Aug 04, 2022

SELL
$19.08 - $26.7 $763 - $1,068
-40 Reduced 0.4%
9,943 $253,000
Q1 2022

May 09, 2022

BUY
$21.19 - $40.01 $13,455 - $25,406
635 Added 6.79%
9,983 $257,000
Q4 2021

Feb 07, 2022

BUY
$30.97 - $54.03 $73,801 - $128,753
2,383 Added 34.21%
9,348 $368,000
Q3 2021

Nov 04, 2021

BUY
$34.9 - $54.54 $6,421 - $10,035
184 Added 2.71%
6,965 $303,000
Q2 2021

Aug 06, 2021

SELL
$38.75 - $51.0 $252,456 - $332,265
-6,515 Reduced 49.0%
6,781 $321,000
Q1 2021

May 06, 2021

BUY
$26.34 - $83.07 $118,450 - $373,565
4,497 Added 51.11%
13,296 $682,000
Q4 2020

Feb 09, 2021

BUY
$25.51 - $43.38 $224,462 - $381,700
8,799 New
8,799 $236,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $982M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.